United Therapeutics Co. (NASDAQ:UTHR) Stock Holdings Lifted by MBM Wealth Consultants LLC

MBM Wealth Consultants LLC raised its position in shares of United Therapeutics Co. (NASDAQ:UTHR) by 1.9% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,151 shares of the biotechnology company’s stock after purchasing an additional 41 shares during the period. MBM Wealth Consultants LLC’s holdings in United Therapeutics were worth $775,000 as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in UTHR. USA Financial Formulas bought a new position in United Therapeutics during the third quarter valued at approximately $33,000. Brooklyn Investment Group bought a new position in shares of United Therapeutics during the 3rd quarter valued at $33,000. Capital Performance Advisors LLP acquired a new stake in shares of United Therapeutics in the 3rd quarter valued at $82,000. MassMutual Private Wealth & Trust FSB boosted its holdings in United Therapeutics by 31.9% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company’s stock worth $85,000 after purchasing an additional 58 shares in the last quarter. Finally, Values First Advisors Inc. acquired a new position in United Therapeutics during the third quarter worth $90,000. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, CFO James Edgemond sold 7,800 shares of the business’s stock in a transaction on Monday, October 28th. The stock was sold at an average price of $350.00, for a total value of $2,730,000.00. Following the sale, the chief financial officer now owns 6,978 shares of the company’s stock, valued at $2,442,300. The trade was a 52.78 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Judy D. Olian sold 1,750 shares of the stock in a transaction on Monday, November 11th. The stock was sold at an average price of $412.48, for a total value of $721,840.00. Following the transaction, the director now owns 5,655 shares of the company’s stock, valued at $2,332,574.40. This represents a 23.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 136,848 shares of company stock worth $51,515,999 over the last quarter. Company insiders own 11.90% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently issued reports on UTHR. UBS Group upped their price target on United Therapeutics from $415.00 to $475.00 and gave the stock a “buy” rating in a research note on Wednesday, January 8th. StockNews.com upgraded United Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Thursday, January 16th. TD Cowen lifted their price target on shares of United Therapeutics from $350.00 to $400.00 and gave the company a “buy” rating in a research report on Monday, October 21st. Argus raised their target price on shares of United Therapeutics from $360.00 to $400.00 and gave the company a “buy” rating in a research note on Thursday, October 31st. Finally, HC Wainwright boosted their target price on shares of United Therapeutics from $400.00 to $425.00 and gave the stock a “buy” rating in a research report on Thursday, October 31st. One research analyst has rated the stock with a sell rating, two have given a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $378.36.

United Therapeutics Trading Up 2.5 %

Shares of NASDAQ UTHR opened at $367.97 on Wednesday. The firm has a market capitalization of $16.43 billion, a price-to-earnings ratio of 16.16, a PEG ratio of 0.92 and a beta of 0.57. United Therapeutics Co. has a one year low of $208.62 and a one year high of $417.82. The business has a fifty day simple moving average of $365.91 and a 200 day simple moving average of $355.01.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.16 by $0.23. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The company had revenue of $748.90 million during the quarter, compared to analysts’ expectations of $722.62 million. During the same quarter in the prior year, the company posted $5.38 EPS. The business’s revenue was up 22.9% on a year-over-year basis. On average, research analysts anticipate that United Therapeutics Co. will post 25.22 earnings per share for the current fiscal year.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.